Show simple item record

dc.contributor.authorChristaki, Eirinien
dc.contributor.authorAnyfanti, Panagiotaen
dc.contributor.authorOpal, Steven M.en
dc.creatorChristaki, Eirinien
dc.creatorAnyfanti, Panagiotaen
dc.creatorOpal, Steven M.en
dc.date.accessioned2018-06-22T09:52:46Z
dc.date.available2018-06-22T09:52:46Z
dc.date.issued2011
dc.identifier.urihttps://gnosis.library.ucy.ac.cy/handle/7/41498
dc.description.abstractCurrently the treatment mainstay of sepsis is early and appropriate antibiotic therapy, accompanied by aggressive fluid administration, the use of vasopressors when needed and the prompt initiation of measures to support each failing organ. Activated protein C and hydrocortisone, when used accordingly can affect mortality. As the pathophysiologic events that take place during sepsis are being elucidated, new molecules that target each step of those pathways are being tested. However, a lot of those molecules affect various mediators of the sepsis cascade including inflammatory cytokines, cellular receptors, nuclear transcription factors, coagulation activators and apoptosis regulators. Over the last decade, a multitude of clinical trials and animal studies have investigated strategies that aimed to restore immune homeostasis either by reducing inflammation or by stimulating the innate and adaptive immune responses. Antibiotics, statins and other molecules with multipotent immunomodulatory actions have also been studied in the treatment of sepsis. © 2011 Expert Reviews Ltd.en
dc.language.isoengen
dc.sourceExpert Review of Anti-Infective Therapyen
dc.subject3 (2
dc.subject4 dimethoxybenzylidene)anabaseinede
dc.subjectHumanen
dc.subjectHumansen
dc.subjectNeurotoxicityen
dc.subjectNephrotoxicityen
dc.subjectReviewen
dc.subjectAntibiotic agenten
dc.subjectDisseminated intravascular clottingen
dc.subjectUnindexed drugen
dc.subjectSepsisen
dc.subjectIntermethod comparisonen
dc.subjectAntibodiesen
dc.subjectUnclassified drugen
dc.subjectCholinergic stimulationen
dc.subjectDrug megadoseen
dc.subjectImmunologic factorsen
dc.subjectPlaceboen
dc.subjectAnti-inflammatory agentsen
dc.subjectHydroxymethylglutaryl coenzyme a reductase inhibitoren
dc.subjectSimvastatinen
dc.subjectNonhumanen
dc.subjectSignal transductionen
dc.subjectKidney dysfunctionen
dc.subjectPathophysiologyen
dc.subjectClinical trials as topicen
dc.subjectBlood clotting disorderen
dc.subjectSeptic shocken
dc.subjectApoptosisen
dc.subjectImmunityen
dc.subjectInnateen
dc.subjectVentilator associated pneumoniaen
dc.subjectAbdominal infectionen
dc.subjectAcute kidney failureen
dc.subjectAcute lung injuryen
dc.subjectAdaptive immunityen
dc.subjectAdenosine a2a receptoren
dc.subjectAdenosine a2a receptor agonisten
dc.subjectAdvanced glycation end product receptoren
dc.subjectAnimalsen
dc.subjectAnti-bacterial agentsen
dc.subjectAnticoagulant agenten
dc.subjectAnticoagulationen
dc.subjectAntiinflammatory agenten
dc.subjectBacterial infectionen
dc.subjectBacterial infectionsen
dc.subjectCeftriaxoneen
dc.subjectClarithromycinen
dc.subjectCommunity acquired pneumoniaen
dc.subjectComplement activationen
dc.subjectComplement inhibitoren
dc.subjectContinuous hemofiltrationen
dc.subjectCoupled plasma filtration adsorptionen
dc.subjectCytofaben
dc.subjectDeviceen
dc.subjectDidemethoxycurcuminen
dc.subjectDiet supplementationen
dc.subjectEndotoxemiaen
dc.subjectEndotoxinen
dc.subjectEritoranen
dc.subjectGram-negative bacteriaen
dc.subjectHemoadsorption deviceen
dc.subjectHigh mobility group b1 protein antibodyen
dc.subjectHospital infectionen
dc.subjectHydrocortisoneen
dc.subjectImmunityen
dc.subjectImmunomodulationen
dc.subjectImmunomodulatory strategiesen
dc.subjectImmunoparalysisen
dc.subjectImmunostimulationen
dc.subjectIncyclinideen
dc.subjectInflammationen
dc.subjectInhibitor proteinen
dc.subjectInter alpha inhibitor proteinen
dc.subjectKidney injuryen
dc.subjectLactoferrinen
dc.subjectLiver injuryen
dc.subjectMiceen
dc.subjectMultiple organ failureen
dc.subjectOxirisen
dc.subjectPolymyxin ben
dc.subjectProtein antibodyen
dc.subjectProtein cen
dc.subjectProtein targetingen
dc.subjectRenal replacement therapyen
dc.subjectRenal tubule assist deviceen
dc.subjectResatorviden
dc.subjectRespiratory failureen
dc.subjectRosiglitazoneen
dc.subjectSuperantigenen
dc.subjectTalactoferrinen
dc.subjectThymosin alpha1en
dc.subjectUlinastatinen
dc.titleImmunomodulatory therapy for sepsis: An updateen
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.1586/eri.11.122
dc.description.volume9
dc.description.issue11
dc.description.startingpage1013
dc.description.endingpage1033
dc.author.facultyΙατρική Σχολή / Medical School
dc.author.departmentΙατρική Σχολή / Medical School
dc.type.uhtypeArticleen
dc.contributor.orcidChristaki, Eirini [0000-0002-8152-6367]
dc.contributor.orcidAnyfanti, Panagiota [0000-0002-5658-4629]
dc.gnosis.orcid0000-0002-8152-6367
dc.gnosis.orcid0000-0002-5658-4629


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record